Bench Side Story continues with Dr Kelsie Raspin, a dedicated Postdoctoral Research Fellow specialising in Cancer Genetics at Menzies Institute for Medical Research, University of Tasmania, AUSTRALIA
Her primary research focus revolves around bridging a critical knowledge gap in the understanding of genetic alterations implicated in prostate cancer initiation and its progression into metastatic forms.
Driven by an unwavering commitment to equitable access to genomic innovation in clinical cancer care, Kelsie aspires to enhance health outcomes not only for her fellow Tasmanians but also for individuals worldwide.
Kelsie’s research is funded through an RHH Research Foundation grant.
-
Applying artificial intelligence to medical imaging for cardiovascular disease detection
Parmida is a software engineer and biomedical scientist whose research focuses on translating novel medical imaging technologies into clinical practice to improve the diagnosis and management of cardiovascular disease.
Her current work applies advanced deep learning techniques to retinal polarization-sensitive optical coherence tomography (PS-OCT) imaging, aiming to generate clinically meaningful biomarkers and predictions of cardiovascular disease. Parmida’s collaboration partners include Fiona Stanley Hospital in Murdoch, Western Australia.
-
Treatment pathways for chronic plantar heel pain
Jason Rogers is a Tasmanian physiotherapist clinician-researcher with a longstanding interest in improving musculoskeletal foot and ankle conditions. He completed his PhD at the Menzies Institute for Medical Research at the University of Tasmania in 2022 investigating the clinical and imaging factors associated with a common foot complaint known as chronic plantar heel pain.
-
CASE STUDY Link between levels of extracellular vesicles in the blood and tissue damage caused by diseases
A landmark study led by WEHI and La Trobe University has found a potential new diagnostic marker that could be used to better detect the level of tissue damage in our bodies.
This study revealed, for the first time, a link between levels of EVs in the blood and tissue damage caused by diseases such as leukaemia.
Researchers hope to leverage the critical new insight to develop a blood test to monitor cancer patients with tissue damage, which could, in future, enhance treatment strategies for blood cancers and other diseases.
